dipyridamole has been researched along with alpha-Galactosidase A Deficiency in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hughes, DA | 1 |
| Mehta, AB | 1 |
1 review available for dipyridamole and alpha-Galactosidase A Deficiency
| Article | Year |
|---|---|
Vascular complications of Fabry disease: enzyme replacement and other therapies.
Topics: alpha-Galactosidase; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Blood Coagulati | 2005 |